Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

NCT04433442 · clinicaltrials.gov ↗
COMPLETED
Status
2324
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie